Download Full Text (962 KB)
The purpose of this research and systematic literature review is to determine if pharmacogenetic testing for the CYP2D6 enzyme responsible for the metabolism of several opiates leads to differences in serum levels, side effects, and treatment outcomes for patients with acute or chronic pain. Much of the presented research indicates an association between CYP2D6 phenotypes and differential treatment outcomes. Poor CYP2D6 metabolizers are shown to be at increased risk of analgesic failure contrasted with ultra-rapid metabolizers demonstrating better analgesic control; however, they had a higher risk of side effects and toxicity. Conflicting data is also demonstrated as well as a lack of conclusions that can be drawn for more intermediate metabolizers. It is known the gene that codes for CYP2D6 is one of many that can affect opiate metabolism. More research is needed that encompasses all of these genes in order to make the findings more applicable to clinical practice.
Physician Assistant Studies
Date of Work
Pharmacogenetic, CYP2D6 enzyme, CYP2D6 phenotypes, opiate metabolism, CYP2D6 Polymorphisms
Runde, Blair, "CYP2D6 Polymorphisms and their Effect on Opiate Metabolism" (2020). Physician Assistant Scholarly Project Posters. 221.